文献速递医学教育与科研方法临床试验与 GCP

对印度临床试验注册库中干预性药物试验数据缺陷的分析

An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry - India.
PubMed 文献 · Trials · 2019-08-28

研究下载了印度临床试验注册库(CTRI)的记录并导入SQLite数据库进行查询,分析了注册试验特定字段的数据质量。发现研究类型分类不清、内部不一致、信息不完整或不标准、数据缺失、名称或分类变体及伦理委员会信息不完整或错误等问题,多数错误率在个位数但部分显著更高。研究提出了改进CTRI未来版本数据质量的建议。

要点

  • CTRI数据库存在研究类型分类不清、内部不一致、信息不完整或不标准、数据缺失、名称或分类变体、伦理委员会信息不完整或错误等问题。
  • 多数问题错误率在个位数,但部分问题错误率显著更高,错误率已按时间计算。
  • 研究建议改进CTRI数据质量,包括更结构化的研究类型分类、使用逻辑规则防止内部不一致、减少自由文本字段、增加必填字段等。

核心结论

  • 正确记录印度每项试验的所有信息是科学和伦理义务;CTRI是一个有价值的数据库,已证明其在改善该国试验记录方面的价值;本文提出的建议将进一步改进它。

研究设计与样本

  • 研究下载了CTRI记录并将数据重新格式化为SQLite数据库后进行查询,必要时还访问了ClinicalTrials.gov的记录。

主要发现

  • 发现CTRI数据库存在多种类别的问题:研究类型分类不清、内部不一致、信息不完整或不标准、数据缺失、名称或分类变体、伦理委员会信息不完整或错误。
  • 多数问题的错误率在个位数,但其他问题错误率显著更高,错误率已按时间计算。

临床怎么用

  • 作者建议通过以下方式改进CTRI未来版本的数据质量:更详尽和结构化的研究类型分类方式;使用逻辑规则防止内部不一致;减少自由文本字段的使用并更多使用下拉菜单;增加更多必填字段;预注册个人和组织名称并在注册试验时从下拉菜单中选择;提供每个伦理委员会的更多信息,包括其地址并将试验站点名称与相关伦理委员会链接。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical Trials Registry - India (CTRI) was established in July 2007 and today hosts thousands of trials, a significant fraction of them registered in the last couple of years. We wished to undertake an up-to-date analysis of specific fields of the registered trials. In doing so we discovered problems with the quality of the data, which we describe in this paper. METHODS: We downloaded CTRI records and reformatted the data into an SQLite database, which we then queried. We also accessed ClinicalTrials.gov records as needed. RESULTS: We discovered various categories of problems with the data in the CTRI database, including (1) a lack of clarity in the classification of Types of Study, (2) internal inconsistencies, (3) incomplete or non-standard information, (4) missing data, (5) variations in names or classification, and (6) incomplete or incorrect details of ethics committees. For most of these problems, error rates have been calculated, over time. Most were found to be in single digits, although others were significantly higher. We suggest how data quality in future editions of CTRI could be improved, including (1) a more elaborate and structured way of classifying the Type of Study, (2) the use of logic rules to prevent internal inconsistencies, (3) less use of free text fields and greater use of drop-down menus, (4) more fields to be made compulsory, (5) the pre-registration of individuals' and organizations' names and their subsequent selection from drop-down menus while registering a trial, and (6) more information about each ethics committee, including (a) its address and (b) linking the name of the trial site to the relevant ethics committee. As we discuss problems with the data of specific fields, we also examine - where possible - the quality of the data in the corresponding fields in ClinicalTrials.gov, the largest clinical trial registry in the world. CONCLUSIONS: It is a scientific and ethical obligation to correctly record all information pertaining to each trial run in India. CTRI is a valuable database that has proved its worth in terms of improving the record of trials in the country. The suggestions made herein would improve it further.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pillamarapu M, Mohan A, Saberwal G, et al. An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry - India. Trials. 2019. PMID: 31455366. doi:10.1186/s13063-019-3592-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。